latest news releases from the newsroom
OTC Stock Review and Amex Review Announce Coverage of AMDL, Inc.
ATLANTA, Aug. 30, 2007 (PRIME NEWSWIRE) -- OTC Stock Review and Amex Review announced today that coverage has been initiated on AMDL, Inc. (AMEX:ADL). AMDL, Inc., headquartered in Tustin, California, owns China's Jade Pharmaceutical, Inc., is currently seeking FDA approval of its DR-70 non-invasive cancer blood test, and has a Combination Immunogene Therapy ("CIT") technology that could lead to a vaccine or possibly treat those already diagnosed with cancer.
Metso to Supply Particleboard Line to Russia
HELSINKI, Finland, Aug. 30, 2007 (PRIME NEWSWIRE) -- Metso Panelboard, a part of Metso Paper business area, will deliver the equipment for a particleboard production line to Ugra-plit PLC in Khanty-Mansiysk, Russia. The parties have agreed not to disclose the value of the order. In general the market value of these types of deliveries is in the range of EUR 20-30 million. The delivery is scheduled for 2008 and start-up for 2009. The Metso scope of delivery will include all main equipment from raw material preparation to storage of sanded board. The equipment for drying and continuous pressing will be delivered by Siempelkamp GmbH & Co. KG. Metso Panelboard will also supply the plant engineering as well as installation and start-up supervision. The new production line will be installed at Ugra-plit's site in Sovetskiy. The new line is designed for an annual production capacity of 150,000 cubic meters and is later expandable to 260,000 cubic meters. The production will be based on sawmill residues such as sawdust and chips. Ugra-plit PLC, established in 2005, is fully owned by the Department of Property of Khanty-Mansiysk Autonomous Region. The investment is part of a forest industry development program of the region.
Talon Therapeutics, Inc.
Hana Biosciences Appoints S. Michael Imperiale, Jr., M.D., as Vice President, Clinical Research Operations
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2007 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on advancing cancer care, today announced the appointment of S. Michael Imperiale, Jr., M.D. as Vice President, Clinical Research Operations. Dr. Imperiale will oversee all aspects of clinical operations related to the development of Hana's drug candidates.